Posts tagged private placement
3DS raises $3.9-million in oversubscribed private placement

3D Signatures (TSX-V:DXD) issued 5,187,618 units under a brokered private placement at a price of 75 cents a unit for gross proceeds of about $3.9-million, including a partial exercise of an over-allotment option.

Read More
GeneNews closes private placement

GeneNews (TSX:GEN) has accepted subscriptions for a non-brokered private placement offering of 9,794,203 units, at a price of 16 cents each, for proceeds of about $1.6-million. 

Each unit consists of one common share and one-quarter of a warrant. Each whole warrant entitles the holder to acquire one common share at a price of 50 cents until August 15, 2018.

Read More
Avivagen closes private placement

Avivagen (TSX-V:VIV) has completed a private placement of brokered and non-brokered components, selling 60 million units for gross proceeds of $3.6-million.

Each unit consists of one common share and one-half of a warrant at a price of six cents a unit. Each whole warrant entitles the holder to acquire one common share of Avivagen at a price of nine cents for two years from closing.

Read More
GeneNews closes note financing with Alumina

GeneNews (TSX:GEN) has executed a definitive financing agreement with Alumina Partners for a second tranche of a non-brokered private placement.

Under the accord, GeneNews will draw down on $10-million in structured, unsecured convertible notes, at the company’s option, in installments of $200,000 over a 24-month period. The initial draw will be limited to $200,000 within the first 120 days. The 12% notes will have a term of one year.

Read More
GeneNews provides financing update

GeneNews (TSX:GEN) has closed the first tranche of a private placement, consisting of the issuance of approximately 5.6 million common shares at a price of 10 cents each, for gross proceeds of approximately $560,000, to be used for working capital.

The company also has executed a term sheet with Alumina Partners for a second tranche, allowing GeneNews to draw down on $10-million (US) in structured, unsecured convertible notes, at the company’s option, in installments of $200,000 over a 24-month period.

Read More
GeneNews arranging private placement

GeneNews (TSX:GEN) is undertaking a non-brokered private placement of up to 50 million common shares at a price of 10 cents apiece, or $5-million.

Any remaining unfunded portion of the offering may be raised with the issuance of a senior secured, collateralized convertible debenture. If needed, this convertible debenture would be issued with a term of one year, interest accrued and payable at 15% and with a conversion price of 16 cents a share.  The conversion would become mandatory if the common stock trades above 16 cents for 30 consecutive trading days.

Read More